» Articles » PMID: 30459713

Intraoperative Decision-Making and Technical Aspects of Parathyroidectomy in Young Patients With MEN1 Related Hyperparathyroidism

Overview
Specialty Endocrinology
Date 2018 Nov 22
PMID 30459713
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

One in 5,000 to 1 in 50,000 births have multiple endocrine neoplasia type 1 (MEN1). MEN1 is a hereditary syndrome clinically defined by the presence of two of the following endocrine tumors in the same patient: parathyroid adenomas, entero-pancreatic endocrine tumors and pituitary tumors. Most commonly, patients with MEN1 manifest primarily with signs and symptoms linked to primary hyperparathyroidism. By age 50, it is estimated that 100% of patients with MEN1 will have been diagnosed with primary hyperparathyroidism. These patients will need to undergo resection of their hyperfunctioning glands, however there is no clear consensus on which procedure to perform and when to perform it in these patients. In this original study we describe and explain the rational of our peri-operative approach and management at MD Anderson Cancer Center of MEN1 patients with hyperparathyroidism. This protocol includes preoperative evaluation, intraoperative decision-making and detailed surgical technique adopted for these patients' care. Additionally we review follow-up and disease management in instances of recurrent primary hyperparathyroidism in patients with MEN1 syndrome.

Citing Articles

Bone mineral density over ten years after primary parathyroidectomy in multiple endocrine neoplasia type 1.

Kuusela E, Kostiainen I, Ritvonen E, Ryhanen E, Schalin-Jantti C JBMR Plus. 2024; 8(12):ziae129.

PMID: 39575107 PMC: 11579653. DOI: 10.1093/jbmrpl/ziae129.


[Special features of the diagnostics and treatment of hereditary primary hyperparathyroidism].

Mogl M, Goretzki P Chirurgie (Heidelb). 2023; 94(7):586-594.

PMID: 37291366 DOI: 10.1007/s00104-023-01897-8.


Update on the clinical management of multiple endocrine neoplasia type 1.

Pieterman C, Valk G Clin Endocrinol (Oxf). 2022; 97(4):409-423.

PMID: 35319130 PMC: 9540817. DOI: 10.1111/cen.14727.


Less than subtotal parathyroidectomy in multiple endocrine neoplasia type 1: A case report and review of the literature.

Kartini D, Dasawala F, Ham M Int J Surg Case Rep. 2020; 77:337-340.

PMID: 33212306 PMC: 7683229. DOI: 10.1016/j.ijscr.2020.10.140.


Multiple Endocrine Neoplasia Type 1 (MEN1): An Update and the Significance of Early Genetic and Clinical Diagnosis.

Kamilaris C, Stratakis C Front Endocrinol (Lausanne). 2019; 10:339.

PMID: 31263451 PMC: 6584804. DOI: 10.3389/fendo.2019.00339.

References
1.
Lambert L, Shapiro S, Lee J, Perrier N, Truong M, Wallace M . Surgical treatment of hyperparathyroidism in patients with multiple endocrine neoplasia type 1. Arch Surg. 2005; 140(4):374-82. DOI: 10.1001/archsurg.140.4.374. View

2.
Marcocci C, Cianferotti L, Cetani F . Bone disease in primary hyperparathyrodism. Ther Adv Musculoskelet Dis. 2012; 4(5):357-68. PMC: 3458615. DOI: 10.1177/1759720X12441869. View

3.
Perrier N . From Initial Description by Wermer to Present-Day MEN1: What have We Learned?. World J Surg. 2018; 42(4):1031-1035. DOI: 10.1007/s00268-017-4435-3. View

4.
Brandi M, Gagel R, Angeli A, Bilezikian J, Beck-Peccoz P, Bordi C . Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab. 2001; 86(12):5658-71. DOI: 10.1210/jcem.86.12.8070. View

5.
Gibril F, Chen Y, Schrump D, Vortmeyer A, Zhuang Z, Lubensky I . Prospective study of thymic carcinoids in patients with multiple endocrine neoplasia type 1. J Clin Endocrinol Metab. 2003; 88(3):1066-81. DOI: 10.1210/jc.2002-021314. View